TXMD
TherapeuticsMD, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$1.86
−2.11%Year over year
Reported trailing growth
- Revenue
- +27.8%
- EBITDA
- —
- EBIT
- -25.6%
- EPS
- +49.7%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +2815.3%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -64.9%
- EBITDA
- +30.3%
- EBIT
- +13.0%
- Net income
- +73.9%
- EPS
- +74.1%
- Free cash flow
- +231.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026